Table 2 Correlation between PRKD alterations and clinicopathologic parameters in polymorphous adenocarcinoma spectrum of tumors
Total (n = 37) | Mutation (n = 14) | Fusion (n = 16) | Wild type (n = 7) | P values | |
|---|---|---|---|---|---|
Architectural patterns | |||||
10% papillae | <0.001 | ||||
Absent | 22 (59%) | 13 (93%) | 4 (25%) | 5 (71%) | |
Present | 15 (41%) | 1 (7%) | 12 (75%) | 2 (29%) | |
30% cribriform | 0.157 | ||||
Absent | 32 (86%) | 10 (71%) | 15 (94%) | 7 (100%) | |
Present | 5 (14%) | 4 (29%) | 1 (6%) | 0 | |
Cribriform% | 13% ± 3% | 21% ± 6% | 9% ± 4% | 6% ± 2% | 0.089 |
Papillary% | 14% ± 3% | 2% ± 1% | 28% ± 6% | 8% ± 6% | <0.001 |
Solid% | 24% ± 3% | 26% ± 5% | 25% ± 4% | 16% ± 4% | 0.824 |
Reticular% | 19% ± 3% | 20% ± 4% | 13% ± 3% | 29% ± 9% | 0.121 |
Single filing% | 4% ± 1% | 7% ± 1% | 2% ± 1% | 3% ± 1% | 0.001 |
Tubular% | 10% ± 1% | 10% ± 2% | 8% ± 1% | 15% ± 4% | 0.333 |
Tubuloreticular% | 17% ± 2% | 15% ± 2% | 16% ± 3% | 23% ± 5% | 0.695 |
Other histologic and clinical features | |||||
Mitotic index | 0.183 | ||||
<5/10 high-power fields | 27 (73%) | 11 (79%) | 9 (56%) | 7 (100%) | |
≥5/10 high-power fields | 10 (27%) | 3 (21%) | 7 (44%) | 0 | |
Tumor size | 0.299 | ||||
≤2 cm | 20 (54%) | 9 (64%) | 7 (44%) | 4 (57%) | |
>2 cm | 17 (46%) | 5 (36%) | 9 (56%) | 3 (43%) | |
Tumor necrosis | 0.045 | ||||
Absent | 32 (86%) | 14 (100%) | 11 (69%) | 7 (100%) | |
Present | 5 (14%) | 0 | 5 (31%) | 0 | |
% of nuclei with clearing | 65% ± 4% | 51% ± 6% | 81% ± 4% | 56% ± 9% | <0.001 |
Outcome | |||||
Follow-up period (months) | 83 ± 12 | 71 ± 18 | 80 ± 20 | 116 ± 24 | 0.739 |
Lymph node status | 0.003 | ||||
N0/Nx | 28 (76%) | 14 (100%) | 8 (50%) | 6 (86%) | |
N1 | 9 (24%) | 0 | 8 (50%) | 1 (14%) | |
Dead of disease | 0 | 0 | 0 | 0 | NA |
Recurrence | 3 (8%) | 1 (7%) | 2 (12.5%) | 0 | 0.630 |
